Innocoll AG (INNL) Lowered to “Hold” at Zacks Investment Research
According to Zacks, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland. “
Separately, FBR & Co began coverage on shares of Innocoll AG in a report on Thursday, June 30th. They issued an “outperform” rating and a $18.00 price target on the stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/innocoll-ag-innl-lowered-to-hold-at-zacks-investment-research.html
Innocoll AG (NASDAQ:INNL) traded down 0.82% during trading on Tuesday, hitting $6.03. 150,859 shares of the company were exchanged. The company has a 50-day moving average of $6.03 and a 200-day moving average of $6.84. The company’s market capitalization is $146.85 million. Innocoll AG has a 12 month low of $4.57 and a 12 month high of $13.72.
Innocoll AG (NASDAQ:INNL) last announced its quarterly earnings results on Wednesday, August 17th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.11. Innocoll AG had a negative net margin of 1,139.95% and a negative return on equity of 1,226.28%. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.04 million. Analysts forecast that Innocoll AG will post ($2.41) EPS for the current year.
Innocoll AG Company Profile
Innocoll Holdings plc is a commercial-stage specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need. The Company utilizes its collagen-based technology platform to develop biodegradable and fully bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innocoll AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll AG and related companies with MarketBeat.com's FREE daily email newsletter.